Table 8.
The use of genetic technique sequencing plus the phenotypic antibiogram. The GeneXpert® via PCR method detected VIM. The phenotypic antibiogram correlates with the MBL detected.
| P. aeruginosa | Blood Culture | |
|---|---|---|
| GeneXprt® | ||
| KPC | Not detected | |
| VIM | Detected | |
| IMP | Not detected | |
| NDM | Not detected | |
| OXA-48 | Not detected | |
| Antibiotic | MIC | SIR * |
| Amikacin | =16.0 | S |
| Cefepime | >16.0 | R |
| Ceftazidime | >64.0 | R |
| Ceftazidime/Avibactam | >64.0 | R |
| Ceftolozane/Tazobactam | >64.0 | R |
| Ciprofloxacin | >1.0 | R |
| Colistin | =1.0 | S |
| Meropenem | >64.0 | R |
| Piperacillin/Tazobactam | >128.0 | R |
| Cefiderocol | ≤2.0 | S |
MIC = minimum inhibitory concentration; SIR = Susceptible (S), Susceptible, Iincreased Eexposure (I), and Resistant (R). * Breakpoint sec. Clinical breakpoints (v 13.1) [44]. Comment: tThe antibiogram shows a resistance profile to all BL and new BL/BLI. Cefiderocol is susceptible. PCR detected VIM. This phenotype is compatible with the VIM MBL P. aeruginosa strain.